Post Doc Fellow, Division of Hematology and Oncology, College of Medicine

Current UC employees must apply internally via SuccessFactors > http://bit.ly/UCEMPL

Founded in 1819, the University of Cincinnati ranks among the nation’s best urban public research universities. Home to more than 47,000 students, 10,500 faculty and staff and 330,000 alumni, UC combines a Top 35 research university with a physical setting The New York Times calls “the most ambitious campus design program in the country.”

With the launch of Next Lives Here, the Cincinnati Innovation District, a $100 million JobsOhio investment, eight straight years of record enrollment, worldwide leadership in cooperative education, a dynamic academic health center and entry into the Big 12 athletic conference, UC’s momentum has never been stronger. UC’s annual budget tops $1.6 billion and its endowment totals $1.9 billion.

Job Overview

As one of the oldest medical schools in the country, the University of Cincinnati College of Medicine (COM) has a reputation for training best-in-class health care professionals and developing cutting-edge procedures and research that improves the health and clinical care of patients. In partnership with the UC Health academic healthcare system and Cincinnati Children’s Hospital Medical Center, College of Medicine’s doctors are transforming the world of medicine every day. The Division of Hematology and Oncology is a top-tier department with world-renowned faculty and staff. With world-class research, teaching and medical practice opportunities, why not choose the University of Cincinnati College of Medicine?

Dr. Vladimir Bogdanov is recruiting a Post Doctoral Fellow to work in his lab focusing on alternatively spliced Tissue Factor (asTF) as a potential therapeutic target in gastrointestinal malignancies. Alternatively spliced Tissue Factor (asTF) is a soluble form of Tissue Factor (TF), the trigger of blood clotting. We were the first to report that asTF is elevated in the cancer lesions and circulating blood of patients suffering from pancreatic ductal adenocarcinoma, and hepatocellular carcinoma. Mechanistically, asTF protein acts as a cell agonist promoting growth and spread of malignant cells; our recently developed inhibitory antibody against asTF is currently being tested in animal models.  Areas of interest include, but not limited to, the consequences of antibody-mediated inhibition of asTF on primary and metastatic tumor growth; the mechanisms regulating asTF biosynthesis in malignant cells; and the potential utility of asTF as a biomarker of disease aggressiveness and/or recurrence.